Literature DB >> 22025578

Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection?

Beatriz Munoz1, Dianne Stare, Harran Mkocha, Charlotte Gaydos, Thomas Quinn, Sheila K West.   

Abstract

PURPOSE: To evaluate combinations of clinical signs, using a modified World Health Organization (WHO) grading scheme, to predict a very low prevalence of infection at the community level after at least three rounds of mass drug administration (MDA).
METHODS: Seventy-one villages had three to seven rounds of MDA. A random sample of 7828 children ages 5 years and younger was evaluated for trachoma, and determination of Chlamydia trachomatis infection was made. Proportions of children positive for infection were evaluated against all possible combinations of follicular trachoma (TF) and inflammatory trachoma (TI). High-risk signs (HRS) for infection were defined as those indicating the infection prevalence was >20%. The sensitivity and specificity of prevalence of HRS in identifying communities with infection was examined.
RESULTS: The median community infection prevalence was 3.8% interquartile range (IQR) (1.8%, 7.7%); the median trachoma prevalence was 9.4%, IQR (6.6%, 15%). Severe TI, combination of TF and TI (WHO criteria), or severe TF with signs of inflammation were predictive of infection in the community, but the absence of these HRS was not an indicator of low infection rates.
CONCLUSIONS: The use of HRS to determine the infection status of a community was not useful in predicting whether MDA could be stopped.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025578      PMCID: PMC3230903          DOI: 10.1167/iovs.11-8074

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

1.  Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.

Authors:  Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West
Journal:  Ophthalmic Epidemiol       Date:  2011-02       Impact factor: 1.648

2.  Slow resolution of clinically active trachoma following successful mass antibiotic treatments.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Jenafir I House; Nisha R Acharya; Travis C Porco; Bruce D Gaynor; Thomas M Lietman
Journal:  Arch Ophthalmol       Date:  2011-04

3.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

4.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Travis C Porco; Elizabeth Yi; Jenafir I House; Zhaoxia Zhou; Kathryn J Ray; Nisha R Acharya; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

5.  Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

6.  Mass treatment with single-dose azithromycin for trachoma.

Authors:  Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

7.  An animal model of trachoma II. The importance of repeated reinfection.

Authors:  H R Taylor; S L Johnson; R A Prendergast; J Schachter; C R Dawson; A M Silverstein
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

8.  Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.

Authors:  Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

9.  Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.

Authors:  Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

10.  Two doses of azithromycin to eliminate trachoma in a Tanzanian community.

Authors:  Anthony W Solomon; Emma Harding-Esch; Neal D E Alexander; Aura Aguirre; Martin J Holland; Robin L Bailey; Allen Foster; David C W Mabey; Patrick A Massae; Paul Courtright; John F Shao
Journal:  N Engl J Med       Date:  2008-04-24       Impact factor: 91.245

View more
  16 in total

1.  Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.

Authors:  Jithin Yohannan; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Robin Bailey; Thomas A Lietman; Thomas Quinn; Sheila K West
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

Review 2.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

3.  Serology for trachoma surveillance after cessation of mass drug administration.

Authors:  Diana L Martin; Rhiannon Bid; Frank Sandi; E Brook Goodhew; Patrick A Massae; Augustin Lasway; Heiko Philippin; William Makupa; Sandra Molina; Martin J Holland; David C W Mabey; Chris Drakeley; Patrick J Lammie; Anthony W Solomon
Journal:  PLoS Negl Trop Dis       Date:  2015-02-25

Review 4.  Social Sciences for the Prevention of Blindness.

Authors:  Pablo Goldschmidt
Journal:  Trop Med Health       Date:  2015-03-25

5.  A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

Authors:  Sheila K West; Robin Bailey; Beatriz Munoz; Tansy Edwards; Harran Mkocha; Charlotte Gaydos; Thomas Lietman; Travis Porco; David Mabey; Thomas C Quinn
Journal:  PLoS Negl Trop Dis       Date:  2013-08-29

6.  CT694 and pgp3 as serological tools for monitoring trachoma programs.

Authors:  E Brook Goodhew; Jeffrey W Priest; Delynn M Moss; Guangming Zhong; Beatriz Munoz; Harran Mkocha; Diana L Martin; Sheila K West; Charlotte Gaydos; Patrick J Lammie
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

Review 7.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

8.  Field evaluation of the Cepheid GeneXpert Chlamydia trachomatis assay for detection of infection in a trachoma endemic community in Tanzania.

Authors:  Alexander Jenson; Laura Dize; Harran Mkocha; Beatriz Munoz; Jennifer Lee; Charlotte Gaydos; Thomas Quinn; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2013-07-04

9.  The limits of medical interventions for the elimination of preventable blindness.

Authors:  Pablo Goldschmidt; Ellen Einterz
Journal:  Trop Med Health       Date:  2014-02-18

10.  Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.

Authors:  Jonathan D King; Tesfaye Teferi; Elizabeth A Cromwell; Mulat Zerihun; Jeremiah M Ngondi; Mesele Damte; Frew Ayalew; Zerihun Tadesse; Teshome Gebre; Ayelign Mulualem; Alemu Karie; Berhanu Melak; Mitku Adugna; Demelash Gessesse; Abebe Worku; Tekola Endashaw; Fisseha Admassu Ayele; Nicole E Stoller; Mary Rose A King; Aryc W Mosher; Tesfaye Gebregzabher; Geremew Haileysus; Peter Odermatt; Jürg Utzinger; Paul M Emerson
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.